Research Studies

Bitch to Quit

The Bitch to Quit smoking cessation research study is closed to additional enrollment. If you participated in the study and are looking for follow-up information, please contact Raymond Ruiz at rar2175@uic.edu or 312.996.7974 with any questions or concerns. Information about study findings will be posted in the near future.

Medication Therapy Management Study

Gilead GS-US-380-1489

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Gilead Sciences, Inc. GS-US-412-2055 Discover Trial

“A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are at Risk of HIV-1 Infection.”

If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email clinicalresearch@howardbrown.org.

Gilead GS-US-380-1490

A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

CHEMBIO DIAGNOSTIC SYSTEMS, INC. CP-HIV-SYPH-03

“Pivotal Clinical Studies for the DPP HIV Syphilis Assay in the Laboratory and at Point-of-Care Sites”

If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email clinicalresearch@howardbrown.org.

CytoDyn, Inc PRO 140_CD 02

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-Arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects.

If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email clinicalresearch@howardbrown.org.

 

Upcoming Events

  1. Illinois Advocacy Day , April 4

    April 4 @ 6:00 am - 7:00 pm
  2. Annual Meeting

    April 5 @ 6:00 pm - 8:00 pm
  3. Garden of Eve: Forward

    April 28 @ 6:00 pm - 10:00 pm
  4. Illinois Advocacy Day, May 17

    May 17 @ 6:00 am - 7:00 pm